Comparison of Antibody- and Cell-Mediated Immune Responses After Intramuscular Hepatitis C Immunizations of BALB/c Mice
Authors:
- 1 December 2005
- journal article
- research article
- Published by SAGE Publications in Viral Immunology
- Vol. 18 (4) , 637-648
Abstract
Current treatments for hepatitis C infection have limited efficacy, and there is no vaccine available. The goal of this study was to compare the immune response to several immunization combinations against hepatitis C virus (HCV). Six groups of mice were immunized at weeks 0, 4, and 8 with different combinations of a candidate HCV vaccine consisting of 100 µg recombinant HCV core/E1/E2 (rHCV) DNA plasmid and/or 25 µg rHCV polyprotein and 50 µL Montanide ISA- 51. Four weeks after the last injection, all groups of mice were sacrificed and blood samples and spleens were collected for measuring the levels of specific HCV antibodies (total IgG, IgG1, and IgG2a). Cell proliferation and intracellular interferon-γ were also measured. Among the groups of immunized mice, only the mice immunized with rHCV DNA plasmid, rHCV polyprotein, and montanide (group D) and mice immunized with rHCV polyprotein and montanide (group F) demonstrated a significant increase in the total IgG titer after immunization. IgG1 was the predominant antibody detected in both groups D and F. No IgG2a was detected in any of the groups. Proliferation assays demonstrated that splenocytes from group D and group C (rHCV DNA primed/rHCV polyprotein boost) developed significant anti-HCV proliferative responses. The combination of an rHCV DNA plasmid, rHCV polyprotein, and montanide induced a high antibody titer with a predominance of IgG1 antibodies and recognized the major neutralization epitopes in HVR1. In contrast, group C did not show an increase in anti-HCV antibodies, but did show a proliferative response.Keywords
This publication has 54 references indexed in Scilit:
- Hepatitis C virus genotype distribution in China: Predominance of closely related subtype 1b isolates and existence of new genotype 6 variantsJournal of Medical Virology, 2005
- Type 1 interferon augments DNA-based vaccination against hepatitis C virus core proteinJournal of Medical Virology, 2004
- CpG Oligodeoxynucleotide and Montanide ISA 51 Adjuvant Combination Enhanced the Protective Efficacy of a Subunit Malaria VaccineInfection and Immunity, 2004
- DNA Immunization with Hepatitis C Virus (HCV) Polycistronic Genes or Immunization by HCV DNA Priming-Recombinant Canarypox Virus Boosting Induces Immune Responses and Protection from Recombinant HCV-Vaccinia Virus Infection in HLA-A2.1-Transgenic MiceJournal of Virology, 2003
- Hepatitis C virus (HCV) E1 and E2 protein regions that specifically bind to HepG2 cellsJournal of Hepatology, 2002
- Induction of Hepatitis C Virus E1 Envelope Protein-Specific Immune Response Can Be Enhanced by Mutation of N-Glycosylation SitesJournal of Virology, 2001
- Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNAHepatology, 2000
- Identification of a murine CD4+ T-lymphocyte response site in hepatitis C virus core proteinMolecular Immunology, 1996
- Use of Intrinsic and Extrinsic Helper Epitopes for In Vivo Induction of Anti-Hepatitis C Virus Cytotoxic T Lymphocytes (CTL) with CTL Epitope Peptide VaccinesThe Journal of Infectious Diseases, 1996
- Direct Gene Transfer into Mouse Muscle in VivoScience, 1990